FORM 6-K
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
Report of Foreign Issuer
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
For the month of March 2020
 
Commission File Number: 001-11960
 
AstraZeneca PLC
 
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F X Form 40-F __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes __ No X
 
If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
 
 
 
 
 
 
 
 
 
 
 
AstraZeneca PLC
 
INDEX TO EXHIBITS
 
 
1.
Director/PDMR Shareholding
 
 
31 March 2020 07:00 BST
 
Transactions by Persons Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
 
AstraZeneca PLC (the Company) announced that, on 27 March 2020, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Performance Share Plan (AZPSP).
 
The AZPSP award was granted on 27 March 2015 and was subject to a three-year performance period followed by a two-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 77% of the AZPSP award vesting and the remaining unvested part lapsing.
 
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:
 
PDMR
Ordinary Shares acquired under the AZPSP
Pascal Soriot
74,698
Marc Dunoyer
19,429
 
For tax purposes, the fair market value of an Ordinary Share at vest was 6882 pence, being the closing price on the last trading day preceding the vesting.
 
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
 
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
a)
 
Name
Pascal Soriot
2
 
Reason for the notification
 
a)
 
Position/status
 
Chief Executive Officer
b)
 
Initial notification /Amendment
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
AstraZeneca PLC
b)
 
LEI
PY6ZZQWO2IZFZC3IOL08
4i
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
 
Description of the financial instrument, type of instrument
 
 
Identification code
Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
b)
 
Nature of the transaction
 
 
Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.
c)
 
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
0
74,698
 
d)
 
Aggregated information
 
- Aggregated volume
- Price
Not applicable - single transaction
 
 
 
 
e)
 
Date of the transaction
 
27 March 2020
f)
 
Place of the transaction
 
Outside a trading venue
 
 
1
 
Details of the person discharging managerial responsibilities / person closely associated
a)
 
Name
Marc Dunoyer
2
 
Reason for the notification
 
a)
 
Position/status
 
Chief Financial Officer
b)
 
Initial notification /Amendment
Initial notification
3
 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
 
Name
AstraZeneca PLC
b)
 
LEI
PY6ZZQWO2IZFZC3IOL08
4i
 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
 
Description of the financial instrument, type of instrument
 
 
Identification code
Ordinary Shares of US$0.25 each in AstraZeneca PLC
 
 
GB0009895292
 
b)
 
Nature of the transaction
 
 
Acquisition of ordinary shares pursuant to a vesting under the AstraZeneca Performance Share Plan, for nil consideration.
c)
 
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
0
19,429
 
d)
 
Aggregated information
 
- Aggregated volume
- Price
Not applicable - single transaction
 
 
 
 
e)
 
Date of the transaction
 
27 March 2020
f)
 
Place of the transaction
 
Outside a trading venue
 
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
Adrian Kemp
Company Secretary
AstraZeneca PLC
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AstraZeneca PLC
 
 
Date: 31 March 2020
 
 
By: /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary